管理神经退行性疾病的生物标志物
Lara Cheslow1,2, Adam E Snook1,3,4, Scott A Waldman1,4
1Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Biomolecules
|April 27, 2024
概括
神经系统疾病是导致残疾的主要原因,预计病例将翻一番. 开发疾病修饰疗法需要确定阿尔茨海默氏症的特定生物标志物.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物标志物发现发现
背景情况:
- 神经系统疾病是全球残疾的主要原因,影响15%的人口.
- 人口老龄化将使神经退行性疾病的患病率在未来20年翻一番.
- 目前的疗法提供症状缓解,但缺乏疾病修饰能力.
研究的目的:
- 突出强调迫切需要疾病修饰疗法用于神经退行性疾病.
- 强调生物标志物在患者识别,疾病监测和治疗目标发现中的关键作用.
- 审查阿尔茨海默病,肌缩侧面硬化症和帕金森病的患病率,机制,临床试验和生物标志物.
主要方法:
- 关于神经系统疾病患病率和人口统计的文献综述.
- 分析当前的治疗策略和未满足的需求.
- 检查生物标志物的作用和潜力在神经退行性疾病研究.
主要成果:
- 生物标志物对于早期检测,疾病分期和跟踪治疗反应至关重要.
- 识别特定的生物标志物可以加速开发新的治疗点.
- 介绍了对阿尔茨海默病,ALS和帕金森病的全面综述.
结论:
- 生物标志物对于指导疾病修饰疗法的发展至关重要.
- 生物标志物将有助于推进阿尔茨海默病,ALS和帕金森病的治疗方法.
- 本综述为未来的神经退行症生物标志物和治疗点研究提供了基础.
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Parkinson's Disease: Overview
537
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
537
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81


